
JELMYTO® Shows 86% Recurrence-Free Survival (RFS) at 24 Months: Real-World AUA 2024 Analysis
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company specializing in urothelial and specialty cancer treatments, presents findings from a sub-analysis of JELMYTO (mitomycin) for pyelocalyceal solution at the American Urological Association Meeting 2024. In a cohort of complete responders to…












